Targeting a common collaborator in cancer development

Sci Transl Med. 2010 Sep 8;2(48):48ps45. doi: 10.1126/scitranslmed.3001251.

Abstract

In this issue of Science Translational Medicine, Wallin et al. have identified a subset of breast and ovarian cancer cell lines that show synergistic response to the combination of doxorubicin and GDC-0941, a class IA phosphatidylinositol 3-kinase (PI3K) inhibitor. Here, we discuss the potential implications of these data on the clinical development of PI3K pathway inhibitors as cancer therapeutics.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology*
  • Antibiotics, Antineoplastic / therapeutic use
  • Biomarkers, Tumor
  • Cell Line, Tumor / drug effects*
  • Doxorubicin / pharmacology*
  • Doxorubicin / therapeutic use
  • Drug Synergism
  • Humans
  • Indazoles / pharmacology*
  • Indazoles / therapeutic use
  • Neoplasms / drug therapy
  • Neoplasms / physiopathology*
  • Phosphoinositide-3 Kinase Inhibitors
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use

Substances

  • 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
  • Antibiotics, Antineoplastic
  • Biomarkers, Tumor
  • Indazoles
  • Phosphoinositide-3 Kinase Inhibitors
  • Sulfonamides
  • Doxorubicin